RBC
VRTX icon

Ronald Blue & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Ronald Blue & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,838
Closed -$296K – 302
2015
Q3 		$296K Sell
2,838
-176
-6% -$22.6K 0.02% 208
2015
Q2 		$372K Sell
3,014
-19
-0.6% -$2.39K 0.02% 217
2015
Q1 		$358K Buy
3,033
+1,236
+69% +$148K 0.02% 224
2014
Q4 		$213K Buy
+1,797
New +$202K 0.01% 308

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ronald Blue & Co's VRTX Position: Q4 2015 in Review

Ronald Blue & Co sold out of Vertex Pharmaceuticals (VRTX) in Q4 2015, closing a stake of 2,838 shares — an estimated $296K sold.

Ronald Blue & Co first reported a position in VRTX in Q4 2014 and held it in 4 quarters. The position peaked at $372K in Q2 2015. 517 funds tracked by Wall St. Rank hold VRTX as of Q4 2015.

  • Ronald Blue & Co reported no remaining Vertex Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Ronald Blue & Co sold 2,838 Vertex Pharmaceuticals shares in Q4 2015, an estimated $296K.
  • Ronald Blue & Co first reported a position in Vertex Pharmaceuticals in Q4 2014 and held it in 4 quarters.
  • Ronald Blue & Co's Vertex Pharmaceuticals position peaked at $372K in Q2 2015.
  • 517 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2015.

Based on Ronald Blue & Co's 13F filing for Q4 2015, filed 11 Feb 2016.